Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months

NCT00635492 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00635492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00635492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2011
Enrollment
2,515 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus